CAR-T or bispecific antibodies for myeloma: how to compare them

Two ways to direct T cells toward myeloma

CAR-T involves collecting and modifying your T cells to recognize a target, such as BCMA, on myeloma cells. The prepared cells are returned after lymphodepleting treatment. A bispecific antibody is a manufactured medicine that connects a T cell to a target on the myeloma cell.

Myeloma bispecific antibodies include BCMA-directed medicines and agents directed at another target, GPRC5D. Ask for both the drug name and the target. This is especially useful if you have already received a BCMA-directed treatment and are considering what should come next.

Sources and references: [1] [2]

Check the current treatment setting for each medicine

The number and type of earlier treatments required differ across products and regimens. For example, the US indication for Carvykti includes at least one prior line containing a proteasome inhibitor and an immunomodulatory agent, with lenalidomide-refractory disease.

Bispecific treatment is also moving into earlier settings. In March 2026, the FDA approved teclistamab with daratumumab and hyaluronidase-fihj for adults after at least one prior line including a proteasome inhibitor and an immunomodulatory agent. Teclistamab used alone retains a different prior-treatment requirement. For Shanghai care, ask the center to check the current Chinese indication and access for the exact regimen.

Sources and references: [3] [4]

How quickly treatment needs to start matters

Autologous CAR-T needs cell collection, manufacturing and checks before infusion. Bridging therapy may be used while the product is prepared. A bispecific antibody does not require individual manufacturing, which can be useful when a treatment needs to start promptly.

The team still needs to complete the assessment and arrange safe first dosing. Ask for the earliest realistic start date for each option and what treatment is needed in the meantime. The comparison should reflect your actual disease pace, including kidney function, symptoms and recent marker changes.

Sources and references: [1] [2]

Compare a concentrated course with repeated dosing

CAR-T usually involves a concentrated treatment period followed by monitoring, with the possibility of time without regular antimyeloma dosing if it works well. Bispecific antibodies are generally given repeatedly according to the regimen, with the interval sometimes changing after a sustained response.

Many bispecific regimens begin with smaller step-up doses and close observation to manage early immune reactions. Ask where these doses are given and when routine treatment could move closer to home. For an overseas patient, repeated visits and medicine access after return are important parts of the decision.

Sources and references: [2] [5] [6]

Both approaches need an infection and reaction plan

CRS and neurological effects can occur with T-cell-directed treatments. Low blood counts and reduced antibody levels can increase infection risk. Ask how the center handles the first treatment period and what prevention and monitoring will continue afterward.

The safety profile also depends on the target and drug. GPRC5D-directed talquetamab can cause changes in taste, skin and nails that may affect eating and daily comfort. CAR-T products have their own specific warnings. Tell the team about previous infections, weight loss and nerve or cognitive symptoms before choosing a regimen.

Sources and references: [2] [6]

Earlier targets influence the next option

Bring records of any prior CAR-T, bispecific antibody or antibody-drug conjugate, including how long the response lasted. These treatments may share a target even when their names sound unrelated. The specialist will consider that exposure alongside the current disease and the evidence for another target.

Ask how choosing one therapy now might affect later options. In some situations the team may consider a different target after relapse; in others, another treatment directed at the same target may still be assessed. A sequencing discussion should include disease urgency and any opportunity for a trial.

Sources and references: [2]

Use results from comparable patients

When comparing benefit, look at the disease setting and earlier treatments, then response depth, duration and survival. A percentage from a heavily pretreated group answers a different question from a study at first relapse. Ask which evidence is closest to your case.

Include the burden of treatment in that comparison. Some people place a high value on fewer ongoing doses; others need an option that can start sooner or be delivered near home. Explain these preferences so the clinician can recommend a plan that fits both the myeloma and your daily life.

Sources and references: [2] [4]

Prepare a comparison for a Shanghai hematology appointment

EastMedGo can help organize the records for a cellular-therapy assessment and a discussion of alternatives. Include the full treatment timeline, recent myeloma markers, marrow findings and any previous target-directed treatment.

When you contact us, state that you want to compare CAR-T with a bispecific regimen, and tell us where you expect to receive ongoing care. We can help clarify the receiving team's document requirements and appointment arrangements, then organize practical questions about initial monitoring, repeated dosing, local stay and the handover home.

Common questions